Introduction
============

As one of the most common primary brain tumors, glioma poses a serious threat to human health. Although the pathogenesis mechanism of glioma is not perfectly illustrated, previous studies have provided substantial evidence that individual's genetic factors, besides external environmental factors, play an important role in the occurrence of glioma.[@b1-ott-10-5297]--[@b4-ott-10-5297]

EGF containing fibulin like extracellular matrix protein 1 (*EFEMP1*) gene, located on chromosome 2p16.1, encodes a member of the fibulin family of extracellular matrix glycoproteins, which contain tandemly repeated epidermal growth factor-like repeats followed by a C-terminus fibulin-type domain. *EFEMP1* plays important roles in the development of many types of cancer, such as ovarian carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and glioma.[@b5-ott-10-5297]--[@b9-ott-10-5297] As for glioma, Hu et al found that *EFEMP1* was consistently upregulated in malignant glioma tissue and promoted tumor cell motility and invasion. Furthermore, *EFEMP1* could promote glioma growth and resistance through a novel paracrine regulation of Notch signaling, suggesting that *EFEMP1* functioned as an oncogene in glioma.[@b10-ott-10-5297],[@b11-ott-10-5297]

Due to the fact that single nucleotide polymorphisms (SNPs) in cancer-related genes have an effect on the occurrence of cancer, the role of *EFEMP1* SNPs in glioma risk has been widely investigated in recent years.[@b10-ott-10-5297]--[@b15-ott-10-5297] However, investigation results for several SNPs (rs3791679 G/A and rs1346786 A/G) were inconsistent. In addition, the single-center study on the association of *EFEMP1* rs1346787 A/G with glioma risk had a poor statistical power due to finite sample size. In order to get a more precise conclusion, a meta-analysis of the associations between common SNPs (rs3791679, rs1346786, and rs1346787) of *EFEMP1* gene and glioma risk was conducted in the present study.

Methods
=======

Literature search
-----------------

PubMed, EMBASE, Web of Science, and Chinese National Knowledge Infrastructure were searched for published articles that assessed the associations of *EFEMP1* SNPs with glioma risk. The cutoff date for searching was April 15, 2017. The search keywords were as follows: ("EGF containing fibulin like extracellular matrix protein 1" OR "EFEMP1") and ("polymorphism" OR "SNP" OR "variant"), and ("glioma" OR "brain tumor"). Only English and Chinese languages were applied in the search process. Furthermore, the reference lists of the obtained articles were also manually screened to identify more potential studies.

Selection criteria and data extraction
--------------------------------------

Two authors independently searched and selected the eligible articles. Eligible articles should meet the following criteria: 1) studies were of case--control design; 2) studies evaluated the associations between *EFEMP1* polymorphisms and glioma risk; 3) studies contained the available data for calculating the odds ratio (OR) and 95% confidence interval (CI); 4) the genotype distribution of the control groups in each study should conform to the Hardy--Weinberg equilibrium (HWE). After obtaining the eligible articles, two authors independently extracted the following data: the first author's surname, year of publication, country, detection method, source of the control group, number of cases and controls, allele and genotype frequencies, and *P*-values for HWE (*P*~HWE~). Finally, any disagreements were resolved by discussion.

Quality evaluation for the eligible articles
--------------------------------------------

Two authors independently assessed the quality of each eligible article according to the Newcastle--Ottawa Scale (NOS). The NOS contained three assessment categories, including selection, comparability, and exposure. In the selection and exposure categories, each eligible item was awarded one star. In the comparability category, each eligible item was awarded no more than two stars.

Statistical analysis
--------------------

HWE was examined by goodness-of-fit chi-square test, and *P*~HWE~ \<0.05 was considered as a deviation from HWE. The strength of associations between *EFEMP1* polymorphisms and glioma risk were evaluated by pooled OR and 95% CI. The significance of the pooled OR was assessed by the *Z*-test, and *P*~Z~ \<0.05 was considered statistically significant. The chi-square-based *Q*-test was applied to investigate the heterogeneity between studies. If the *P*~H~ ≤0.1 indicated the existence of between-study heterogeneity, the random-effects model was applied to calculate the pooled OR; otherwise, the fixed-effects model was used in the analysis. As for *EFEMP1* rs3791679 polymorphism, sensitivity analysis was conducted by sequentially omitting one study at a time to assess the stability of the result. Furthermore, publication bias for *EFEMP1* rs3791679 polymorphism was determined by Begg's funnel plots and Egger's test. All statistical tests were implemented in the Review Manager (version 5.2; Cochrane Collaboration, London, UK) or Stata 12.0 (version 12.0; StataCorp, College Station, TX, USA).

Results
=======

Characteristics of the included studies
---------------------------------------

A total of 12 potential articles were obtained after searching databases ([Figure 1](#f1-ott-10-5297){ref-type="fig"}). Further analysis found that four studies with the same quality could be included in the present meta-analysis ([Table 1](#t1-ott-10-5297){ref-type="table"}). These eligible studies contained 1,582 cases and 2,283 controls, and were conducted in the Chinese population. A total of 14 SNPs were investigated in *EFEMP1* gene ([Table 2](#t2-ott-10-5297){ref-type="table"}). Among these SNPs, significant associations of rs1346787, rs3791679, rs1346786, and rs3791675 with glioma risk were observed in at least one study. However, detection methods for *EFEMP1* SNPs, including TaqMan, polymerase chain reaction-restriction fragment length polymorphism, and MassARRAY, were not exactly the same in these studies. Considering that rs1346787, rs3791679, and rs1346786 polymorphisms might affect individual risk of developing glioma and were assessed in more than one study, we extracted genotype frequencies of these polymorphisms ([Table 3](#t3-ott-10-5297){ref-type="table"}).

Meta-analysis results
---------------------

[Table 4](#t4-ott-10-5297){ref-type="table"} shows the main results of the overall meta-analysis. No significant heterogeneity was observed for rs1346787 and rs1346786 polymorphisms. Thus, fixed-effects model was used to assess the strength of the association. Results showed that rs1346787 polymorphism was significantly associated with glioma risk under all genetic models (GG vs AA, OR =2.22, 95% CI =1.46--3.36; AG vs AA, OR =1.54, 95% CI =1.27--1.87; (GG+AG) vs AA, OR =1.60, 95% CI = 1.34--1.93; GG vs (AG+AA), OR =1.86, 95% CI =1.24--2.78; G vs A, OR =1.54, 95% CI =1.32--1.79). However, the significant association of rs1346786 polymorphism with glioma risk was only observed under heterozygous model of AG vs AA (OR =1.34, 95% CI =1.10--1.62), dominant model of (GG+AG) vs AA (OR =1.36, 95% CI =1.13--1.63), and allelic model of G vs A (OR =1.28, 95% CI =1.10--1.50). For rs3791679 polymorphism, random-effects model was adopted due to the existence of heterogeneity. When all the eligible studies were pooled into the meta-analysis of rs3791679 polymorphism, no significant association was observed under all genetic models (AA vs GG, OR =1.42, 95% CI =0.69--2.92; AG vs GG, OR =1.26, 95% CI =0.94--1.69; (AA+AG) vs GG, OR =1.26, 95% CI =0.88--1.82; AA vs (AG+GG), OR =1.40, 95% CI =0.80--2.46; A vs G, OR =1.21, 95% CI =0.88--1.68).

Sensitivity and publication bias analysis for rs3791679 polymorphism
--------------------------------------------------------------------

Sensitivity analysis for rs3791679 polymorphism was performed by omitting one study at a time ([Table 5](#t5-ott-10-5297){ref-type="table"}). Results showed that the overall effect changed noticeably after omitting Jiang et al's study[@b13-ott-10-5297] (AA vs GG, OR =2.05, 95% CI =1.55--2.71; AG vs GG, OR =1.35, 95% CI =1.17--1.56; (AA+AG) vs GG, OR =1.49, 95% CI =1.18--1.89; AA vs (AG+GG), OR =1.81, 95% CI =1.38--2.37; A vs G, OR =1.45, 95% CI =1.18--1.78).

Begg's funnel plots and Egger's test were used to assess the publication bias for rs3791679 polymorphism. As shown in [Figure 2](#f2-ott-10-5297){ref-type="fig"}, Begg's funnel plots did not show any obvious asymmetry. In addition, *P*-values of Egger's test were more than 0.05 under all genetic models (AA vs GG, *P*=0.254; AG vs GG, *P*=0.624; (AA+AG) vs GG, *P*=0.611; AA vs (AG+GG), *P*=0.789; A vs G, *P*=0.492). These results suggested lack of publication bias.

Discussion
==========

In recent years, the associations between common SNPs within *EFEMP1* gene and glioma risk have been investigated in the Chinese population. However, only rs1346787, rs3791679, and rs1346786 polymorphisms might play an important role in glioma risk. Considering that inconsistent results were reported in rs3791679 and rs1346786 polymorphisms, we applied a meta-analysis, which was a powerful tool for analyzing cumulative data of studies, to get more precise estimation. Results of meta-analysis showed that *EFEMP1* rs1346786 polymorphism was significantly associated with an increased risk of glioma in Chinese population under heterozygous model of AG vs AA, dominant model of (GG+AG) vs AA, and allelic model of G vs A. However, the association of *EFEMP1* rs3791679 with glioma risk was not observed in overall meta-analysis. Interestingly, the overall effect of *EFEMP1* rs3791679 polymorphism on glioma risk changed noticeably after omitting Jiang et al's study.[@b13-ott-10-5297] The phenomenon might be due to the fact that sample sizes were small in Jiang et al's study compared with those in the three other studies, which could make allele and genotype frequency distribution of rs3791679 polymorphism more easily deviate from the actual distribution. The change hinted that the overall results of rs3791679 polymorphism were unstable and needed to be treated cautiously. Although the consistent results of *EFEMP1* rs1346787 polymorphism were observed in Yang et al's[@b12-ott-10-5297] and Zhang et al's[@b15-ott-10-5297] studies, single-center study had a poor statistical power due to finite sample size. Thus, meta-analysis was used to further assess the role of *EFEMP1* rs1346787 polymorphism in glioma risk. Results indicated that *EFEMP1* rs1346787 polymorphism was significantly associated with an increased risk of glioma.

Several limitations of the present meta-analysis should be considered. Firstly, the unadjusted estimates were used in the present meta-analysis, while a more precise analysis should be performed if individual lifestyle and environmental factors are available. Furthermore, our meta-analysis was restricted to the Chinese and English languages, which might result in potential language bias. Last but not least, the function of these risk alleles was not identified in traditional epidemiology research. As a promising direction, a molecular pathologic epidemiology approach could be used to find the function of these risk alleles. For example, risk alleles could be hypothesized to regulate the expression of *EFEMP1* gene. Thus, the relationship between risk alleles and *EFEMP1* gene expression in glioma tissue could be examined.

Conclusion
==========

We found significant associations between rs1346787 and rs1346786 polymorphisms within *EFEMP1* gene and glioma risk in Chinese population. However, more case--control studies need to be conducted in the Chinese population to verify the above-mentioned findings.
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###### 

Quality evaluation of the eligible articles

  Categories                                            Items                                          Yang et al[@b12-ott-10-5297] study             Jiang et al[@b13-ott-10-5297] study            Qin et al[@b14-ott-10-5297] study              Zhang et al[@b15-ott-10-5297] study
  ----------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Selection                                             Adequacy of case definition                    [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}
  Representativeness of the cases                       [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   
  Selection of controls                                 [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   
  Definition of controls                                [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   
  Comparability Exposure                                Comparability of cases/controls                [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}
  Ascertainment of exposure                             [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   
  Same method of ascertainment for cases and controls   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   [\*](#tfn1-ott-10-5297){ref-type="table-fn"}   
  Non-response rate                                     --                                             --                                             --                                             --                                             

**Note:**

Eligible item according to the Newcastle--Ottawa scale.

###### 

The main characteristics of the eligible studies

  Study                           Year of publication   Country     Detection method   Source     Cases   Controls   SNPs        Base change   Gene location of SNPs   Association with glioma risk
  ------------------------------- --------------------- ----------- ------------------ ---------- ------- ---------- ----------- ------------- ----------------------- ------------------------------
  Yang et al[@b12-ott-10-5297]    2017                  China       TaqMan             Hospital   350     706        rs1346787   A/G           3′near gene             Yes
  rs3791679                       G/A                   Intron 10   Yes                                                                                                
  rs17047290                      A/G                   Intron 5    No                                                                                                 
  Jiang et al[@b13-ott-10-5297]   2016                  China       PCR-RFLP           Hospital   94      206        rs3791679   G/A           Intron 10               Yes
  Qin et al[@b14-ott-10-5297]     2015                  China       PCR-RFLP           Hospital   159     364        rs3791679   G/A           Intron 10               Yes
  rs1346786                       A/G                   Intron 5    No                                                                                                 
  rs1344733                       A/G                   Intron 4    No                                                                                                 
  rs727878                        A/G                   Intron 5    No                                                                                                 
  Zhang et al[@b15-ott-10-5297]   2015                  China       MassARRAY          Hospital   979     1,007      rs1346787   A/G           3′near gene             Yes
  rs3791679                       G/A                   Intron 10   Yes                                                                                                
  rs17047290                      A/G                   Intron 5    No                                                                                                 
  rs1346786                       A/G                   Intron 5    Yes                                                                                                
  rs3791675                       A/G                   Intron 4    Yes                                                                                                
  rs10496055                      A/G                   Intron 4    No                                                                                                 
  rs10865291                      A/G                   Intron 4    No                                                                                                 
  rs727878                        A/G                   Intron 4    No                                                                                                 
  rs1344733                       A/G                   Intron 4    No                                                                                                 
  rs3791661                       A/G                   Intron 4    No                                                                                                 
  rs3791660                       A/C                   Intron 4    No                                                                                                 
  rs1430195                       A/G                   Intron 4    No                                                                                                 
  rs7559906                       A/G                   Intron 4    No                                                                                                 
  rs4233964                       A/G                   Intron 4    No                                                                                                 

**Abbreviations:** PCR, polymerase chain reaction; SNPs, single nucleotide polymorphisms; RFLP, restriction length polymorphism.

###### 

The genotype frequencies of *EFEMP1* rs1346787, rs3791679, and rs1346786 polymorphisms

  Study                           rs1346787 (cases)       rs1346787 (controls)       *P*~HWE~                                                   
  ------------------------------- ----------------------- -------------------------- ----------- -------- -------- -------- ----------- ------- -------
  Yang et al[@b12-ott-10-5297]    157                     150                        43          350      414      245      47          706     0.193
  Zhang et al[@b15-ott-10-5297]   825                     146                        8           979      894      107      6           1,007   0.159
                                                                                                                                                
                                  **rs3791679 (cases)**   **rs3791679 (controls)**                                                              
  **GG**                          **GA**                  **AA**                     **Total**   **GG**   **GA**   **AA**   **Total**           
                                                                                                                                                
  Yang et al[@b12-ott-10-5297]    170                     139                        41          350      444      225      37          706     0.228
  Jiang et al[@b13-ott-10-5297]   14                      43                         37          94       13       87       106         206     0.382
  Qin et al[@b14-ott-10-5297]     58                      73                         28          159      171      154      39          364     0.624
  Zhang et al[@b15-ott-10-5297]   595                     331                        53          979      667      301      38          1,006   0,579
                                                                                                                                                
                                  **rs1346786 (cases)**   **rs1346786 (controls)**                                                              
  **AA**                          **AG**                  **GG**                     **Total**   **AA**   **AG**   **GG**   **Total**           
                                                                                                                                                
  Qin et al[@b14-ott-10-5297]     51                      76                         32          159      129      168      67          364     0.347
  Zhang et al[@b15-ott-10-5297]   716                     241                        22          979      798      193      14          1,005   0.551

**Abbreviation:** HWE, Hardy--Weinberg equilibrium.

###### 

Meta-analysis of the associations between *EFEMP1* SNPs and glioma risk

  SNP ID          Comparison   *P*~H~    Model     *P*~Z~                  OR (95% CI)
  --------------- ------------ --------- --------- ----------------------- -----------------------
  rs1346787       GG vs AA     0.38      F         \<0.001                 **2.22 (1.46--3.36)**
  AG vs AA        0.65         F         \<0.001   **1.54 (1.27--1.87)**   
  (GG+AG) vs AA   0.38         F         \<0.001   **1.60 (1.34--1.93)**   
  GG vs (AG+AA)   0.54         F         0.003     **1.86 (1.24--2.78)**   
  G vs A          0.48         F         \<0.001   **1.54 (1.32--1.79)**   
  rs3791679       AA vs GG     \<0.001   R         0.34                    1.42 (0.69--2.92)
  AG vs GG        0.03         R         0.13      1.26 (0.94--1.69)       
  (AA+AG) vs GG   0.002        R         0.21      1.26 (0.88--1.82)       
  AA vs (AG+GG)   \<0.001      R         0.24      1.40 (0.80--2.46)       
  A vs G          \<0.001      R         0.24      1.21 (0.88--1.68)       
  rs1346786       GG vs AA     0.40      F         0.12                    1.40 (0.92--2.12)
  AG vs AA        0.42         F         0.003     **1.34 (1.10--1.62)**   
  (GG+AG) vs AA   0.39         F         0.001     **1.36 (1.13--1.63)**   
  GG vs (AG+AA)   0.37         F         0.23      1.27 (0.86--1.86)       
  G vs A          0.19         F         0.001     **1.28 (1.10--1.50)**   

**Note:** Bold values indicate statistical significance.

**Abbreviations:** *P*~H~, *P* value of heterogeneity; *P*~Z~, *P* value of Z test; OR, odds ratio; SNPs, single nucleotide polymorphisms; R, random-effects model; F, fixed-effects model.

###### 

The association of *EFEMP1* rs3791679 with glioma risk after omitting Jiang et al's study[@b13-ott-10-5297]

  SNP ID          Comparison   *P*~H~   Model     *P*~Z~              OR (95% CI)
  --------------- ------------ -------- --------- ------------------- -------------------
  rs3791679       AA vs GG     0.17     F         \<0.001             2.05 (1.55--2.71)
  AG vs GG        0.29         F        \<0.001   1.35 (1.17--1.56)   
  (AA+AG) vs GG   0.10         R        \<0.001   1.49 (1.18--1.89)   
  AA vs (AG+GG)   0.30         F        \<0.001   1.81 (1.38--2.37)   
  A vs G          0.05         R        \<0.001   1.45 (1.18--1.78)   

**Abbreviations:** *P*~H~, *P* value of heterogeneity; *P*~Z~, *P* value of Z test; OR, odds ratio; SNP, single nucleotide polymorphism; R, random-effects model; F, fixed-effects model.
